2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2684

Regional and Whole Gut Transit Times in Patients with Systemic Sclerosis Using the Wireless Motility Capsule
Abstract Number: 2685

Sensitivity and Specificity of YKL-40 for the Presence of Pulmonary Arterial Hypertension in Systemic Sclerosis
Abstract Number: 2686

In Established Pulmonary Arterial Hypertension the Follow-up Cardiac Catheterization-Derived Pulmonary Artery Systolic Pressure and Vascular Resistence May be Predicted By Echocardiography- a Longitudinal Study in Two Connective Tissue Disease Cohorts
Abstract Number: 2687

Characteristic of Pulmonary Arterial Hypertension in Patients with Anti-U1RNP Antibody-Positive-Connective Tissue Diseases Is Determined By the Underlying Disease Rather Than Autoantibody Profile
Abstract Number: 2688

Collagen Metabolite Biomarker Levels Are Associated with the Amount of Fibrosis in Internal Organs in Systemic Sclerosis Patients
Abstract Number: 2689

Troponinemia Independently Associates with Mortality in Systemic Sclerosis
Abstract Number: 2690

Plasma D-Dimer Levels Are More Frequently Elevated in Limited Than Diffuse Cutaneous Systemic Sclerosis but Do Not Reflect Disease Duration or Vasculopathy
Abstract Number: 2691

Increased Circulating Cadherin-11 Levels in Patients with Systemic Sclerosis
Abstract Number: 2692

Vitamin D Deficiency in Systemic Sclerosis Patients: Relations with Multiple Clinical Parameters and Standard Treatment
Abstract Number: 2693

Relationships between Levels of Patient Activation, Self-Efficacy, and Demographic Variables in Systemic Sclerosis
Abstract Number: 2694

Performance of Patient-Reported Outcomes Measurement Information Systems (PROMIS) Promis-29 and Promis Self-Efficacy in Systemic Sclerosis (SSc)
Abstract Number: 2695

Latent Profile Analysis-Derived Typologies of Systemic Sclerosis Patients Using Body Image Indicators: A Scleroderma Patient-Centered Intervention Network (SPIN) Cohort Study
Abstract Number: 2696

Things Left Unsaid: Important Topics That Are Not Discussed between Patients with Systemic Sclerosis, Their Carers and Their Healthcare Professionals
Abstract Number: 2697

Systemic Sclerosis Quality of Life Questionnaire (SScQoL) Captures the Complex Problems Experienced By Patients with Scleroderma
Abstract Number: 2698

IL-21-mTOR Axis Blocks the Differentiation and Function of SLE Tregs Via Suppression of Autophagy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].